03/09/24 -"Following the company’s profit warning, we have cut our 2024 EBITDAR forecast from €822m to €728m (-11.4%), mainly to reflect the tougher post-scandal rebuild in French nursing homes (revenue -3.2% ..."
Pages
55
Language
English
Published on
03/09/24
You may also be interested by these reports :
12/09/25
DiaSorin appears to be making significant progress in the testing space. The launch of speciality tests, introduction of the Plex platform, and ...
05/09/25
Bastide reported FY24/25 revenue in line with guidance and our forecast. The more technical business activities remain the primary driver of organic ...
05/09/25
Since we last pushed Philips’ (Buy; Netherlands) investment case in January 2024, its share price performance has been glaringly ahead of the MedTech ...
04/09/25
bioMerieux’s H1 profitability surpassed expectations. Topline growth was driven by robust performance across both segments. However, weakness in ...